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ABSTRACT: Despite encapsulation of drugs claim to improve 
the therapeutic profile of free drugs, there are still important 
limitations in drug delivery. Focusing on cancer treatment, two 
promising implementations are combination therapy and tar-
geted devices, aimed at increasing the drug effect either by 
achieving higher cell death rates or by discriminating between 
cell populations. However, for the time being, the scope of com-
bining both approaches is unknown. To advance this knowledge, 
there has been designed a two-drug delivery system with dual 
cell-organelle targeting based on Mesoporous Silica Nanoparti-
cles, known to be able to host drugs within their pores. In vitro 
results show a synergistic effect and high efficacy, demonstrating that the combination of dual therapy and targeting 
could still advance the development of drug delivery nanodevices against difficult-to-treat cancers. 
INTRODUCTION 
Cancer therapy with nanotechnology has been enor-
mously based on the Enhanced Retention and Permeation 
Effect (EPR) discovered in the mid-80s by Matsumura and 
Maeda.1 This effect is a spontaneous preferential accumu-
lation of macromolecules and nanometric materials with-
in solid tumors. This occurs due to a combination of two 
tumor-specific effects: first an excessive and aberrant 
vascularization that allows the particles to escape from 
the blood vessel and second, an absence of lymphatic 
drainage that prevents their elimination. This phenome-
non has been widely employed to efficiently deliver nano-
encapsulated chemotherapeutics to tumor areas while 
minimizing the off target drug uptake.2 These results have 
been successfully exported to clinical practice, reducing 
both side effects and dosage of chemotherapy. However, 
the development of new nanomedicines require from 
increased efficiencies able to outrange the lone effect of 
EPR.3 Currently, one promising trend is to turn nanomed-
icines from passively accumulated carriers to engineered 
devices able to actively address particular cell populations 
onto which exert their apoptotic effect.4 Regarding the 
targeting approach, many examples have been reported 
using antibodies and aptamers as targeting moieties;5–8 
unfortunately, the high associated costs and low chemical 
stability of antibodies and the limited number of available 
aptamers penalize their use as all-purpose targeting tags. 
These drawbacks have increased the interest for more 
robust elements based on small molecules and peptides, 
which despite having lower specificity, are highly compat-
ible with most of production processes: chemical modifi-
cation, thermal treatments, sterilization processes, etc. 
Another important approach for the development of anti-
cancer agents is the maximization of their apoptotic ef-
fect,9 which could be achieved by the simultaneous appli-
cation of independent proapoptotic therapies.10-14 For 
instance, photothermal and photodynamic therapies,14, 15 
siRNAs gene expression disruption,16 immunotherapy17 
and hyperthermia18, 19 in combination with classic chemo-
therapeutic compounds. However, the combination of 
anticancer drugs species remains as one of the approaches 
with more potential and yet less exploited; issue which 
could be achieved with properly engineered nanocarri-
ers.20–23  
Focusing on the construction of multi-targeted delivery 
systems, tissue-cell or cell-cell sequential targeting would 
be more interesting for homing carriers towards tumors 
with poor or without EPR effect, while the cell-organelle 
targeting may be of preference for the treatment of multi-
drug resistant tumors or those which show a strong EPR 
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 effect. In short, the choice of the different targeting units 
must be adapted to the chosen disease. Additionally in 
order to achieve improved antiproliferative effects and 
due to the growing problem of drug resistance,24 it has 
become of extraordinary importance the development of 
drug delivery systems able to disrupt cell replication at 
different points.13, 25–27 To try to outrange the limitations of 
current nanomedicine, many different approaches based 
on different materials came to light;23 but among them, 
mesoporous silica nanoparticles (MSNs)28–33 are of special 
interest because of their unique porous and compart-
mentalized structure that permits to load drugs within the 
pores without affecting the surface. Interesting examples 
dealing with combination therapy employing MSNs could 
be found on a recent review.14 Therein, and as far as we 
know, there are no examples with double-targeted devices 
able to deliver two (or more) drugs; which is relevant to 
establish the potential of these kind of multifunctional 
systems. 
The usual approaches for the development of particles 
with dual targeting properties are fundamentally limited 
to systems obtained upon random surface functionaliza-
tion.14, 34, 35 Other promising strategy employs Janus type 
MSNs functionalized with different molecules in each 
hemisphere.36 Nevertheless, both strategies lead to uncer-
tainty in both composition and ligand ratio, making the 
results also subject to certain randomness. Therefore, to 
obtain optimal targeting results, it is of capital importance 
to reduce this uncertainty. We believe that this problem 
could be solved with the creation multifunctional building 
blocks that after a proper assembly onto particles, would 
provide those with all the functionalities. 
 
RESULTS AND DISCUSSION 
Based on the absence of knowledge about the potential 
behavior of multifunctional targeted nanosystems for 
multiple cytotoxic delivery, we decided to tackle the topic 
using a building block methodology that allowed to in-
corporate those multiple functionalities. To address this 
proof of concept we focused on the sequential cell-
organelle targeting approach, which could be validated 
with simple 2D cell cultures. 
According to our initial premise of employing small 
molecules, a preliminary bibliographic study restricted the 
candidates to: folic acid, biotin, RGD, TAT and KALA 
peptides for cellular targeting5,6 and triphenyl phosphoni-
um cations (TPP), L-carnitine, dexamethasone, colchicine 
and some specific peptides for organelle targeting.37,38 
Among those, because of synthetic simplicity and previ-
ous experimental experience, we decided to carry on our 
studies with folic acid, biotin and TPP as reference target-
ing units. 
In order to implement a sequential dual cell-organelle 
targeting strategy,39 the most logic approach is that which 
places the membrane recognition fragment in the outer-
most part of the particle and the organelle binding ele-
ment in a more internal position. This configuration is 
expected to produce maximal cellular uptake given the 
increased exposure of the membrane ligand. Moreover, is 
also expected that the cationic TPP fragment may facili-
tate interaction between ligands and negatively charged 
membranes.  
With this layered assembly, the incorporation of 
additional functionalities could be achieved by employing 
suitable building blocks. For example, the incorporation 
of a cytotoxic compound could be performed by simply 
adding an additional, more internal, building block 
containing the drug. An important advantage of this 
strategy is that only the surface of MSNs is comprised, 
which leave the mesopores unoccupied, allowing the 
loading of a second cytotoxic drug (Figure 1).  
Figure 1. The multilayer strategy employed for the de-
velopment of dual targeted two-drug nanocarriers based 
on mesoporous silica nanoparticles. 
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 The starting amino-capped fluorescent MSNs (F*MSN-
NH2) were obtained following a two-step methodology. 
First, there were prepared the corresponding fluorescent-
labelled MSNs following a modified Stöber methodology 
and then were reacted with 3-aminopropyl triethoxysilane 
to incorporate the corresponding amino functionality. 
Finally, the surfactant template was removed throughout 
acidic extraction steps with ethanolic NH4NO3 to provide 
the desired MSNs. The physicochemical characterization 
of the prepared material was in agreement with the values 
obtained for porous MCM-41 type materials. The porosity 
of the material was determined by N2 adsorption isotherm 
employing the Brunnauer-Emmet-Teller (BET) approach 
to determine surface area (745.2 m2 g-1) which followed a 
type IV isotherm. The Barrett-Joyner-Halenda (BJH) cal-
culation also provided pore diameter distributions opti-
mal for small-molecule hosting (2.4 nm). The porosity of 
the material was also corroborated in the step prior to 
loading, finding that the F*MSN-Lys-(SSLinker-CPT)-
Lys(TPP)GABA-Biotin hybrid was still suitable for small 
molecule hosting, (2.53 nm, 412.9 m2 g-1, Figure S1) despite 
the expected pore volume reduction induced by the heavy 
surface functionalization (Figure S1). The IR analysis of all 
prepared Mesoporous Organosilica Hybrids (MOSHs) 
showed the typical Mesoporous Silica adsorption bands 
and the expected modifications for each new incorporated 
moiety (Figure S8). The small-angle X-ray scattering of 
F*MSN-NH2 showed the typical long-range ordering dif-
fraction pattern for MCM-41 mesoporous silica with the 
100, 110 and 200 peaks as the most representative. Again, 
this pattern was maintained throughout the whole syn-
thetic process, thus demonstrating that porosity was not 
affected (Figure S2). The particle size, morphology and 
ordered MCM-41-type pattern of the prepared F*MSN-
NH2 could be also observed on the TEM images included 
in the supporting information (Figures S6, S7). 
The dynamic-light scattering (DLS) analysis of the dif-
ferent hybrids showed hydrodynamic diameter values 
starting from 200 nm of the F*MSN-NH2 with logic in-
creases along with the functionalization with the different 
targeting fragments (Figure 2). Despite there are found 
slight variations for average measurements for Folic and 
TPP substituted particles, the raw data show comparable 
sizes according to the magnitude of the incorporated 
modification (Figure S3). Regarding the z-potential, there 
could be observed that all hybrids show positive values, 
according to the nature of the targeting moieties em-
ployed. For single targeted hybrids, the highest values of 
were obtained for TPP (+32.6 mV) and Folic acid (+32.5 
mV) substitutions, while biotin modification provided a 
lower value (+18 mV). In the case of double targeted hy-
brids, the potential values decreased as the separation 
between TPP and biotin augmented. This is a logic effect 
as the TPP, placed on more internal position is more 
shielded as the spacer magnitude is increased (Figure 2). 
All these hybrids have outstanding dispersibility conse-
quence of their functionalization with highly hydrophilic 
fragments.  
The incorporation of the cleavable CPT-containing (HO-
SSLinker-CPT) fragment, although in a more internal 
layer, affected both hydrodynamic size and surface 
potential. As could be seen on figure 2, size values were 
increased in about 40 nm for CPT-modified particles for 
comparable cases (biotin and Lys(TPP)GABA-Biotin). 
Something similar occurred with the z-potential value, 
probably due to the hydrophobic contribution of 
SSLinker-CPT, which in the case of Lys(TTP)GABA-Biotin 
hybrid led to a potential decrease of about 5 mV. In any 
case, the similar values obtained between CPT-containing 
and non-containing particles seem to indicate that the 
internal Lys(SSLinker-CPT) modification is placed far from 
the outer shell and ensures an appropriate exposition of 
the targeting moieties (Figure 2).  
The thermogravimetric analysis (TGA) of the different 
hybrids clearly showed an organic matter increase form 
the 12% of F*MSN-NH2 to about 20% for mono-targeted 
hybrids (Figure S9, up). This pattern is however not main-
tained in the case of bifunctional ligands. In these cases, 
was observed that Lys(TPP)PEG-Biotin (≈ 26%) and non-
spaced bifunctional Lys(TPP)Biotin (≈ 23%) modifications 
leaded to greater mass losses than the two GABA-
Figure 2. Hydrodynamic diameters (red) and z-
potential values (blue) obtained by Dynamic Light Scat-
tering (DLS) for all reported hybrids. Data showed cor-
respond to a mean of 5 measures and were recorded in 
distilled water. Please check Figures S3 and S4 in the 
supporting information for raw data of these measure-
ments. Dual refers to TPP-Biotin double targeted ligands 
with the indicated connectivity. Values for DOX-loaded 
particles could be found on figure S5. 
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 Figure 4. Prepared single and double targeted fluorescein labeled organosilica nanohybrids. Cell uptake measured by flow 
cytometry at 2 h of internalization in HOS cells. Data are mean ± SEM of 3 independent experiments performed in tripli-
cate *p < 0.05 vs HOS control;**p < 0.05 vs F*MSN-NH2; ***p < 0.01 vs F*MSN-NH2; #p < 0.01 vs all groups. 
containing hybrids  (≈ 17 and 21%). Those variations could 
be understood considering the growing steric hindrance 
of ligands, which eventually may block some anchoring 
positions. Regarding the PEG-spaced bis-targeted materi-
al, there should be accounted that the employed 27mer 
PEG has an enormous organic matter contribution and 
that was synthetized following a different strategy, which 
makes its comparison poorly relevant (Figure S9, down). 
The analysis of the drug containing F*MSN-Lys-(SSLinker-
CPT)-Lys(TPP)GABA-Biotin hybrid behaved as expected, 
increasing the organic matter by 8%. The second drug 
loading process, the incorporation of DOX into meso-
pores, increased again the decomposable matter in an 
additional 6% (Figure S10).  
As will be discussed below, the two-drug system 
designed is capable of producing cell death with high 
efficiency. However, given that the release of both drugs 
does not occur simultaneously, it is also important to 
know the release patterns of both species. To determine 
the fate of both drugs there were carried out comparative 
experiments in a simulated intracellular environments 
with the DOX@F*MSN-Lys(SSLinker-CPT)Lys(TPP)GABA-
Biotin hybrid. According to the described procedure the 
release experiment was carried out in 10 mM DTT 
containing PBS (pH=7.4) to mimic the presence of 
intracellular Glutathione. The results showed different 
release profiles for both drugs. DOX, at the pores, showed 
a sustained, almost linear release (17, 30 and 40% at 24, 48 
and 72h); while CPT, grafted on the surface throughout a 
cleavable linker, suffered from a potential-like, faster 
cleavage (40, 50 and 55% for the same times). Regardless 
of the release kinetics followed by each drug, it is 
observed that complete release was reached at about 240h 
(Figure 3).  
The tested MOSHs were prepared from F*MSN-NH2 in a 
single coupling step with the corresponding mono- or 
bifunctional ligands according to the experimental proce-
dure detailed below. (Figure 4) The preparation of the 
TPP-Biotin bifunctional ligands was accomplished em-
ploying the orthogonally protected Lysine supported onto 
Wang’s resin, according to the procedure described on the 
supporting information.  
The uptake ratio obtained for the three single targeted 
MOSHs on mouse pre-osteoblastic MC3T3-E1 cells and on 
Human Osteosarcoma (HOS) cells40,41 showed that Biotin 
(ca. 50%) targeted particles provided better 
internalization than folate (ca. 40%) and TPP (ca. 40%) 
targeted particles. However, since the TPP was the only 
organelle targeting molecule preselected, it will be 
included onto the bifunctional ligands (Figures 4, S11-S13). 
When the Lys(TPP)Biotin targeted MOSHs uptake was 
evaluated against HOS cell line, there was found a 
significant reduction of the internalization, indicating that 
both targeting elements (TPP and Biotin) interfered with 
each other on this particular setup.  
To overcome this problem, there were prepared three 
different MOSHs with increased space between both tar-
geting units. To make the system as much biocompatible 
Figure 3. Simultaneous drug release obtained for 
DOX@F*MSN-Lys(SSLinker-CPT)-Lys(TPP)GABA-Biotin 
obtained at 37ºC during 14 days. The μg quantities noted 
on the release graph express the interpolated release 
values adjusted for the actual amount of hybrid 
employed. The calculated 96 μg estimated for CPT, 
correspond to a functionalization yield of about 9% 
(referenced to the maximum number of available NH2 
groups, supporting information). 
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 as possible, there were chosen γ-aminobutyric acid 
(GABA) as short connecting unit and a bifunctional ami-
noacid containing PEG as long spacer (HO2C-PEG27mer-
NH2); in both cases as their protected Fmoc analogs. The 
preparation of the spaced dual targeted ligands could be 
found on the supporting information. Uptake ratio of 
these MOSHs showed that elongated bifunctional ligands 
improved overall internalization, which leaped up from 
less than 40% of the F*MSN-Lys(TTP)-Biotin to more than 
70% in the cases of F*MSN-Lys(TTP)GABA-Biotin and 
F*MSN-Lys(TTP)PEG-Biotin hybrids (Figures 4 and 5). 
Despite this similarity, there was found a maximal fluo-
rescence intensity on the hybrids modified with 
Lys(TTP)GABA-Biotin, (Figure S13) which will be em-
ployed as reference targeting building block for the fol-
lowing investigations. 
It is interesting to note that the incorporation of any 
spacer, independently from its magnitude, between both 
targeting units enhance internalization above the values 
obtained for the two single targeted particles. However, 
this effect does not seem to occur in the case of for 
F*MSN-Lys(TTP)GABA-GABA-Biotin, which show compa-
rable values to those obtained for Biotin mono-targeted 
MSNs. However this apparent diverging behavior could be 
explained upon analysis of thermogravimetric curves 
obtained for its organic matter decomposition. (Figure S9) 
Those clearly show lower mass loss, which indicates a 
lower number of ligands and therefore, lower internaliza-
tion. 
Once the bifunctional targeting ligand has been select-
ed, to continue advancing in the idea of the multifunc-
tional device, is necessary to include an additional build-
ing block at the surface to allow the inclusion of a drug. 
Among all antiproliferative drugs, there were chosen 
Camptothecin (CPT) and Doxorubicin (DOX) as two ref-
erence antitumor agents with specificity against topoiso-
merases I and II respectively; from which may be expected 
an enhanced cell death induction when combined. To 
facilitate the incorporation of both antitumor species, we 
decided to load DOX into the pores while CPT would be 
incorporated in a new building block at the surface. The 
chosen drug location obeys to the nice behavior shown by 
DOX in both of loading and release processes from silica’s 
mesopores, as recurrently demonstrated on the literature.  
In order to maximize the effect of the surface-bounded 
drug two premises must be complied: first the drug 
should be bounded throughout a cleavable bond to facili-
tate its release and second, this bond must not affect its 
activity. The advantages of employing CPT plus a redox-
sensitive traceless connection42 are the following: a low 
number of functional groups which reduce the possibility 
of side reactions, CPT is recovered in its active form, in-
tracellular release is the only possibility and finally, the 
active region of CPT is not altered. The preparation of the 
cystamine-based cleavable linker43 and its later coupling 
with CPT (HO-SSLinker-CPT) is detailed on the support-
ing information.  
The construction of targeted hybrid systems modified 
with CPT was made from Lys(Fmoc)Mtt functionalized 
MOSHs which were submitted to Mtt deprotection and 
coupled with the corresponding ligand through the 
terminal amino moiety; then after Fmoc cleavage, the HO-
SSLinker-CPT building block was bound to the α-NH2 
moiety. The non-targeted hybrid (F*MSN-Lys(SSLinker-
CPT)NH2) was prepared in a three-step sequence 
involving Fmoc cleavage, coupling with HO-SSLinker-CPT 
and Mtt deprotection. Next, the CPT-containing hybrids 
(F*MSN-Lys(SSLinker-CPT)-Ligand) and their equivalent 
analogs without such modification, (F*MSN-Ligand) were 
loaded with DOX and subjected to viability assay (Figure 
6). 
As expected, it was found that systems without drugs led 
to higher viabilities, perhaps reduced a membrane desta-
Figure 5. Representative fluorescence microscopy images of HOS cells incubated with fluorescein labeled nanoparticles at 
2h of internalization. Blue fluorescence (nuclei), red (actin filaments) and green fluorescence (fluorescein labeled nanopar-
ticles). 
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 bilizing effect attributable to the TPP; whilst the presence 
of cytotoxic agents increased the mortality. In the case of 
systems including a single cytotoxic species, a substantial 
reduction in cell death was hardly achieved, which may 
point out drug-resistance. Regarding the case of two-drug 
systems there was obtained a marked death induction, 
which seems to indicate a cooperative apoptotic effect. It 
is noteworthy that although complete drug release was 
achieved within 10 days, the synergic therapeutic effect 
came earlier. Indeed, after 48h, a very sharp drop in 
viability could be observed (Figures 6 and 7). This effect, 
which seem to be aligned with a significant release of both 
DOX and CPT (30 and 50% of the total load), pointed out 
that in less than 24h, only CPT apoptotic mechanism 
operated. The similar viability values found for 48 and 72h 
suggest that both optimal concentration of CPT and DOX 
was reached during the first two days of incubation. 
It is also remarkable that two examples moved away 
from the expected mortality trend: the non-targeted, two-
drug hybrid and the system that combines DOX and TPP-
Biotin Dual Ligand (Figure 6). The first result could be 
understood considering that the free amino groups at the 
surface could produce a non-specific uptake upon 
interaction with the membranes. To demonstrate this 
postulate there was also prepared a MOSHs bearing an 
inactive targeting, the neutral but polar 4-Nitrobenzoic 
acid. When this non-active targeted F*MSN-Lys(SSLinker-
CPT)NO2 hybrid was compared with the other targeted 
devices, there was found an enhanced cell survival. 
(Figure 7) This highlights an unspecific amino-mediated 
uptake and proves the importance of targeting to 
maximize tumor-delivery. Unfortunately, since this 
unspecific electrostatic induced uptake cannot be used to 
discriminate between different cell types, it is of little 
interest for the development of anticancer therapeutics. 
The second diverging result, single-drug DOX 
chemotherapeutic in combination with the dual ligand 
Lys(TPP)GABA-Biotin, is harder to explain because 
mitochondrial targeting may be acting as destabilizing 
agent and thus enhancing mortality. In any case, this 
result also provides invaluable information since it 
validates the efficiency of our dual cellular-organelle 
targeted nanodevice for the design of more efficient, new 
generation, drug delivery systems.  
CONCLUSIONS 
Figure 6. Cytotoxicity assay measured by Alamar Blue in HOS cells with the different nanoparticles loaded with DOX, CPT 
or both at 24h (A) 48 h (B) and 72h (C) of cell culture. Data are mean ± SEM of 3 independent experiments performed in 
triplicate. *p < 0.05 vs corresponding non-targeted, Biotin or dual nanoparticles. NONE/DOX, particles refer to DOX load-
ed F*MSN-NH2 (DOX@F*MSN-NH2), NONE/CPT refers to F*MSN-Lys(SSLinker-CPT)NH2 and NONE/CPT+DOX to 
DOX@F*MSN-Lys(SSLinker-CPT)NH2. Notation employed for other hybrids is equivalent, with the proviso that Dual refers 
to Lys(TPP)GABA-Biotin targeting ligand. 
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 Despite the use of nanoparticles in medicine has opened 
new possibilities for advanced cancer treatment, the reali-
ty is that a surface functionalization is required to reach 
their maximum potential. On this contribution we de-
scribe a multifunctional two-drug, double vectored 
nanodevice based on Mesoporous Silica, which was built 
by layered assembly of different functional building 
blocks. This system, which according to our knowledge is 
the first of its kind, proposes a sequential cell-organelle 
targeting plus two-drug delivery. This dual release is 
based on combining spontaneous diffusion from a pore-
loaded drug (DOX) together with a dithiol-mediated 
cleavage of a surface-bound antitumor drug (CPT). More-
over it has been optimized a novel membrane-organelle 
dual targeting ligand, which has demonstrated to be more 
efficient than independent targeting fragments. This high-
ly positive result opens an access point to the develop-
ment of more double-targeted ligands employing more 
specific components. The in vitro results of internalization 
and viability against HOS cells demonstrate that this hy-
brid system shows its best performance at 48h, where the 
maximal apoptosis induction is obtained. In view of these 
results, the future work will deal with the implementation 
of this two-drug delivery system with high affinity target-
ing moieties, the implementation of a triple tissue-
membrane-organelle targeting ligands and in vivo testing. 
EXPERIMENTAL SECTION 
Reagents and equipment: Ammonium nitrate, 
Cetyltrimethylammonium bromide (CTAB), Tetraethyl 
orthosilicate (TEOS), Biotin, Folic acid, 1-
Hydroxybenzotriazole (HOBt), N,N,N′,N′-Tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexafluorophosphate 
(HBTU), 4-Nitrobenzoic acid, N-(3-
Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochlo-
ride (EDC), 4-(Fmoc-amino)butyric acid (Fmoc-GABA-
OH), O-(2-Carboxyethyl)-O′-[2-(Fmoc-amino)-
ethyl]heptacosaethyleneglycol (HO-PEG27mer-NHFmoc), 
(4-Carboxybutyl)-triphenylphosphonium bromide (TPP), 
diisopropylethylamine (DIPEA), 4-dimethylaminopyridine 
(DMAP), (S)-(+)-Camptothecin (CPT), DL-Dithiothreitol 
(DTT) and Sephadex G-25 were purchased from Sigma-
Aldrich; from ABCR were obtained 3-
aminopropyltriethoxysilane (APTES), Fluorescein isothio-
cyanate (FITC) and Doxorubicin hydrochloride (DOX). 
The two lysine modified reagents: free and Wang’s resin-
bounded N-α-Fmoc-N-ε-4-methyltrityl-L-lysine (HO-
Lys(Fmoc)Mtt) and [Wang]-Lys(Fmoc)Mtt) were obtained 
from Novabiochem. Cell culture media DMEM, Fetal Bo-
vine Serum and trypsin were purchased from Life Tech-
nologies while the Alamar Blue solution from AbD Sero-
tec. All compounds and solvents were employed without 
additional purification. Prepared materials were analyzed 
employing the available instruments: Philips X-Pert MPD 
diffractometer equipped with CuKα radiation for X-ray 
diffraction (XRD), Perkin-Elmer Pyris Diamond TG/DTA 
analyzer for thermogravimetry and differential tempera-
ture analyses (TGA/DTA), Nicolet Nexus (Thermo Scien-
tific) spectrometer equipped with a Smart Golden Gate 
ATR accessory for Fourier transform infrared (FTIR) spec-
tra and a Bruker AV 250 MHz for NMR experiments. 
Freeze-dying was carried out in a Telstar LyoQuest appa-
ratus. Particles’ morphology was analyzed by transmission 
electron microscopy (TEM) was carried using a JEOL JEM 
2100 microscope equipped with a CCD camera (KeenView 
Camera). Pore properties were determined by N2 adsorp-
tion isotherms on a Micromeritics ASAP 2020 instrument; 
the surface area was obtained by applying the Brunnauer, 
Emmet & Teller (BET) method to the isotherm while pore 
size distribution was determined by the Barrett, Joyner & 
Halenda (BJH) method from the desorption branch of the 
isotherm. The zeta potential and hydrodynamic diameter 
of nanoparticles were measured by means of a Zetasizer 
Nano ZS (Malvern Instruments) equipped with a 633 nm 
laser. Ultraviolet-visible spectra were recorded in a Helios 
Zeta or Unicam UV-500 spectrometers from Thermo Sci-
entific employing 1 cm optical way, reduced volume cu-
vettes. Fluorescence microscopy was performed on an 
Evos FL Cell Imaging System equipped with tree led 
channels (DAPI/GFP/RFP) from AMG (Advance Micros-
copy Group). Fluorescence spectrometry for drug release 
Figure 7. Cytotoxicity assay measured by Alamar Blue in HOS cells for differently targeted MOSHs (4-NO2Bz, Biotin and 
Lys(TPP)GABA-Biotin) with DOX, CPT or both at 48 h of cell culture. Data are mean ± SEM of 3 independent experiments 
performed in triplicate. *p < 0.05 vs corresponding 4-NO2Bz, (4-Nitrobenzoyl) Biotin or dual targeted hybrids; #p < 0.001 vs 
corresponding 4-NO2Bz, Biotin or dual targeted hybrids. Dual refers to Lys(TPP)GABA-Biotin targeting ligand. 
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 studies was performed in a synergy 4 microplate reader 
from BioTek. Flow cytometry data were obtained from a 
FACScan machine (Becton, Dickinson and Company, 
USA).  
Synthesis of amino-capped fluorescent Mesoporous 
Silica Nanoparticles: F*MSN-NH2 nanoparticles were 
synthesized employing a modified Stöber methodology in 
which a mixture of TEOS (5 mL) and fluorescein labeled 
APTES (1 mg FITC plus 2.2 μL APTES reacted in 20 μL 
ethanol for 2h) were dropwise added (0.25 mL min-1) over 
a heated (80ºC) solution of CTAB (1 g) and NaOH (2 M, 
3.5 mL) 480 mL in bidistilled water under stirring. Once 
the addition was concluded, the mixture was stirred for 2 
additional hours to finish the silica condensation. Then, 
the mixture was submitted to usual centrifugation step 
(10000 rpm, 10 min) and repeated washings with water 
(2x200 mL) and ethanol (2x100 mL) to remove the excess 
of reagents. The obtained fluorescent MSNs were then 
dispersed in EtOH (500 mL) and reacted with APTES (200 
µL) at 45ºC for 24 h to functionalize the outer silica 
surface. Once the particles were capped with the amino 
moieties, the surfactant contained within the pores was 
removed by ionic exchange throughout 2 hour reflux 
cycles with extracting solution (2x250 mL of a 10 g L-1 of 
NH4NO3 in 95:5 ethanol-water) followed by 
centrifugation. Finally, the obtained particles were washed 
with EtOH (3x100 mL), dried, dispersed in DMF (20 mg 
mL-1) and stored refrigerated. 
Solid-phase synthesis of bifunctional ligands: The 
synthesis of TPP and Biotin containing ligands was ac-
complished throughout the solid phase methodology 
described on the supporting information. Briefly, the 
synthetic protocol involved Fmoc deprotection of the 
commercial [Wang]-Lys(Fmoc)Mtt resin, followed by 
coupling with TPP. Then, after cleavage of the Mtt pro-
tecting group were coupled the lysine with either a Fmoc-
protected spacer or with the terminal biotin. In the case 
coupling with spacer, an additional Fmoc deprotection 
and coupling step was accomplished. Finally the bifunc-
tional ligand was cleaved from the resin employing a 
TFA/H2O/Et3SiH (95/2.5/2.5) mixture. Ligand purification 
was done by Sephadex G-25 size exclusion chromatog-
raphy with H2O as eluent and isolated by lyophilization.  
Synthesis of targeted Mesoporous OrganoSilica Hy-
brids (MOSHs): The syntheses of single and double tar-
geted MOSHs was accomplished in a single step form the 
prepared F*MSN-NH2 and the appropriate 
mono/bifunctional ligand following one of the described 
coupling protocols described on the supporting infor-
mation. For the PEG spaced dual targeted hybrids there 
was followed a stepwise procedure also detailed on the 
supporting information. Once the targeted MOSHs were 
obtained, they were isolated by centrifugation, washed 
with DMF (2x20 mL) and ethanol (2x20 mL) and stored 
refrigerated at work concentration (20 mg mL-1) in EtOH.  
Synthesis of Camptothecin-modified targeted 
MOSHs: The synthesis of CPT modified hybrids started 
from the lysine modified particles (≈100 mg scale) which 
were submitted to a two-step deprotection-coupling se-
quence. Briefly the followed steps include Mtt deprotec-
tion, coupling with the corresponding ligand, (4-
nitrobenzoic acid, biotin or HO-Lys(TPP)GABA-Biotin), 
Fmoc cleavage and finally, coupling with the Camptothe-
cin dithiol linker. Protocols are detailed on the supporting 
information. 
Loading protocol for Doxorubicin: For the optimal 
diffusion of the drug in between the mesopores, 10 mg of 
the corresponding MOSHs were set under vacuum at 80ºC 
for 2h to remove remainder solvent and volatile com-
pounds. To the vacuumed MOSHs were added 2 mL of a 
saturated solution of DOX in MeOH, this mixture was 
kept for 24h at RT to allow full diffusion throughout the 
mesopores. After completion, the loaded particles were 
centrifuged, washed with MeOH (2x2 mL) and H2O (5x2 
mL) to remove DOX excess. The particles were stored 
with refrigeration as centrifuged and used immediately.  
Drug release studies: Drug release studies were carried 
out with a pur-A-lizerTM mini 6000 dialysis kit filled with a 
suspension of DOX-loaded F*MSN-Lys(SSLinker-CPT)-
Lys(TPP)GABA-Biotin in bidistilled water (3 mg mL-1, 1 
mL). The filled kit was inserted into a reaction vessel con-
taining 10 mL of  0.1 M solution of DTT in PBS. From the 
supernatant were taken aliquots (200 µL) at indicated 
times for fluorescence measurements of released CPT 
(λex= 370 nm, λem= 434 nm) and DOX (λex=470 nm, 
λem=595 nm).
44,45  
Cell cultures: Cell culture tests were performed using 
MC3T3-E1 (mouse pre-osteoblastic cells) and HOS cells 
derived from a human osteosarcoma (CRL-1543; ATCC, 
Mannassas, VA). The different types of nanoparticles (100 
µg mL-1) were placed into each well of 6- or 12-well plates 
(Corning, CULTEK, Madrid, Spain) after cell seeding. Cells 
were then plated at a density of 1.5x104 cells cm-2 in Dul-
becco’s modified Eagle’s medium (DMEM, Sigma Chemi-
cal Company), respectively, containing 10% of heat-
inactivated fetal bovine serum (FBS, Thermo Fisher Scien-
tific) and 1% penicillin–streptomycin (Thermo Fisher 
Scientific) at 37 ºC in a humidified atmosphere of 5% CO2, 
and incubated for different times. Some wells contained 
no nanoparticles as controls. 
Cell viability studies: HOS proliferation was deter-
mined by addition of Alamar Blue solution at 10% (v/v) to 
the cell culture at 24 and 48h of grown, after 2h of nano-
particles internalization, following manufacturer’s instruc-
tions. Fluorescence intensity was measured using excita-
tion emission wavelengths of 570 and 600 nm respective-
ly, in a Unicam UV-500 UV–visible spectrophotometer.  
Cell uptake studies: MC3T3-E1 and HOS cells were cul-
tured in each well of a 6-well plate. After 24h, the cells 
were incubated at different times in the absence or pres-
ence of the tested nanoparticles (100 µg mL-1). After 2h, 
cells were washed twice with PBS and incubated at 37 ºC 
with trypsin–EDTA solution (Sigma-Aldrich) for cell de-
tachment. The reaction was stopped with culture medium 
after 5 min and cells were centrifuged at 1000 rpm for 10 
min and suspended in fresh medium. Then, the surface 
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 fluorescence of the cells was quenched with trypan blue 
(0.4%) to confirm the presence of an intracellular, and 
therefore internalized, fluorescent signal. Flow cytometry 
measurements were performed at an excitation wave-
length of 488 nm, green fluorescence was measured at 530 
nm (FL1). The trigger was set for the green fluorescence 
channel (FL1). The conditions for the data acquisition and 
analysis were established using negative and positive con-
trols with the CellQuest Program of Becton–Dickinson 
and these conditions were maintained during all the ex-
periments. Each experiment was carried out three times 
and single representative experiments are displayed. For 
statistical significance, at least 104 cells were analyzed in 
each sample in a FACScan machine (Becton, Dickinson 
and Company, USA) and the mean of the fluorescence 
emitted by these single cells was used. 
Fluorescence microscopy: HOS cells were incubated 
with the nanoparticles (100 µg mL-1) for 2h. Each well was 
washed with cold PBS for three more times to get rid of 
the nanoparticles not internalized into the cells, and then 
fixed with 75% ethanol (kept at -20 ºC) for 10 min. After 
the ethanol was suck and washed three times with cold 
PBS, actin filaments were stained in red with Alexa Fluor® 
555 Phalloidin (Thermo Fisher Scientific) for 15 min at 1:30 
in BSA. The nuclei of HOS cells were stained with 4',6-
Diamidine-2'-phenylindole dihydrochloride (DAPI, ≥ 98%, 
Sigma-Aldrich) for 5 min, respectively, and then washed 
three times with cold PBS. Fluorescence microscopy of 
nanoparticles internalized by HOS cells were performed 
with an Evos FL microscope employing the following 
wavelengths (λex (nm); λem (nm)): DAPI (357-44; 447-60), 
GFP (470-22; 525-50), RFP (531-40; 593-40). Red channel 
was used to label the cytoplasm, green for nanoparticles 
and blue for cell nucleus. 
Statistical analysis: Results are expressed as mean ± 
SEM. Statistical evaluation was carried out with 
nonparametric Kruskal-Wallis test and post hoc Dunn’s 
test, when appropriate. A value of p < 0.05 was considered 
significant. 
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Figure 1. The multilayer strategy employed for the devel-opment of dual targeted two-drug nanocarriers 
based on mesoporous silica nanoparticles.  
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Figure 2. Hydrodynamic diameters (red) and z-potential values (blue) obtained by Dynamic Light Scat-tering 
(DLS) for all reported hybrids. Data showed correspond to a mean of 5 measures and were record-ed in 
distilled water. Please check Figures S3 and S4 in the supporting information for raw data of these meas-
urements. Dual refers to TPP-Biotin double targeted ligands with the indicated connectivity. Values for DOX-
loaded particles could be found on figure S5.  
 
169x195mm (150 x 150 DPI)  
 
 
Page 13 of 18
ACS Paragon Plus Environment
Bioconjugate Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
Figure 3. Simultaneous drug release obtained for DOX@F*MSN-Lys(SSLinker-CPT)-Lys(TPP)GABA-Biotin 
obtained at 37ºC during 14 days. The µg quantities noted on the release graph express the interpolated 
release values adjusted for the actual amount of hybrid employed. The calculated 96 µg estimated for CPT, 
correspond to a functionalization yield of about 9% (referenced to the maximum number of available NH2 
groups, supporting information).  
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Figure 4. Prepared single and double targeted fluorescein labeled organosilica nanohybrids. Cell uptake 
measured by flow cytometry at 2 h of internalization in HOS cells. Data are mean ± SEM of 3 independent 
experiments performed in triplicate *p < 0.05 vs HOS control;**p < 0.05 vs F*MSN-NH2; ***p < 0.01 vs 
F*MSN-NH2; #p < 0.01 vs all groups.  
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Figure 5. Representative fluorescence microscopy images of HOS cells incubated with fluorescein labeled 
nanoparticles at 2h of internalization. Blue fluorescence (nuclei), red (actin filaments) and green 
fluorescence (fluorescein labeled nanoparticles).  
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Figure 6. Cytotoxicity assay measured by Alamar Blue in HOS cells with the different nanoparticles loaded 
with DOX, CPT or both at 24h (A) 48 h (B) and 72h (C) of cell culture. Data are mean ± SEM of 3 
independent experiments per-formed in triplicate. *p < 0.05 vs corresponding non-targeted, Biotin or dual 
nanoparticles. NONE/DOX, particles refer to DOX loaded F*MSN-NH2 (DOX@F*MSN-NH2), NONE/CPT refers 
to F*MSN-Lys(SSLinker-CPT)NH2 and NONE/CPT+DOX to DOX@F*MSN-Lys(SSLinker-CPT)NH2. Notation 
employed for other hybrids is equivalent, with the proviso that Dual refers to Lys(TPP)GABA-Biotin targeting 
ligand.  
 
278x187mm (150 x 150 DPI)  
 
 
Page 17 of 18
ACS Paragon Plus Environment
Bioconjugate Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
Figure 7. Cytotoxicity assay measured by Alamar Blue in HOS cells for differently targeted MOSHs (4-NO2Bz, 
Biotin and Lys(TPP)GABA-Biotin) with DOX, CPT or both at 48 h of cell culture. Data are mean ± SEM of 3 
independent experiments performed in triplicate. *p < 0.05 vs corresponding 4-NO2Bz, (4-Nitrobenzoyl) 
Biotin or dual targeted hybrids; #p < 0.001 vs corresponding 4-NO2Bz, Biotin or dual targeted hybrids. Dual 
refers to Lys(TPP)GABA-Biotin targeting ligand.  
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